Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Ivana Yen, Fergus Shanahan, Jeeyun Lee, et al.
Nature (2021) Vol. 594, Iss. 7863, pp. 418-423
Closed Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
The RASopathies: from pathogenetics to therapeutics
Katie E. Hebron, Edjay R. Hernandez, Marielle E. Yohe
Disease Models & Mechanisms (2022) Vol. 15, Iss. 2
Open Access | Times Cited: 115
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 95
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 91
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikos I. Poulikakos, Ryan J. Sullivan, Rona Yaeger
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4618-4628
Open Access | Times Cited: 80
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 38
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Melody Riaud, Jennifer Maxwell, Isabel Soria‐Bretones, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 2, pp. 105-122
Closed Access | Times Cited: 21
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance
Wen Li, Xiaoxian Shi, C. S. Tan, et al.
Nature Chemical Biology (2025)
Closed Access | Times Cited: 2
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
Emre Tkacik, Kunhua Li, Gonzalo L. González‐Del Pino, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 5, pp. 104634-104634
Open Access | Times Cited: 32
Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fabian Fröhlich, Luca Gerosa, Jeremy Muhlich, et al.
Molecular Systems Biology (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 30
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Combination of bulk RNA sequencing and scRNA sequencing uncover the molecular characteristics of MAPK signaling in kidney renal clear cell carcinoma
Xiunan Li, Hewen Guan, Chuanyu Ma, et al.
Aging (2024) Vol. 16, Iss. 2, pp. 1414-1439
Open Access | Times Cited: 9
Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF Inhibitors
Joseph Clayton, Aarion Romany, Evangelia Matenoglou, et al.
(2025)
Open Access | Times Cited: 1
Structural basis for SHOC2 modulation of RAS signalling
Nicholas P. D. Liau, Matthew C. Johnson, Saeed Izadi, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 400-407
Open Access | Times Cited: 30
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Cell Reports (2022) Vol. 38, Iss. 6, pp. 110351-110351
Open Access | Times Cited: 28
New Approaches to Targeted Therapy in Melanoma
Manuel Felipe Fernandez, Jacob Choi, Jeffrey A. Sosman
Cancers (2023) Vol. 15, Iss. 12, pp. 3224-3224
Open Access | Times Cited: 20
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B. Ryan, Bradley Quade, Natasha Schenk, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1190-1205
Open Access | Times Cited: 7
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
Transformer-Based Generative Model Accelerating the Development of Novel BRAF Inhibitors
Lijuan Yang, Guanghui Yang, Zhitong Bing, et al.
ACS Omega (2021) Vol. 6, Iss. 49, pp. 33864-33873
Open Access | Times Cited: 40
Harness the functions of gut microbiome in tumorigenesis for cancer treatment
Mong‐Hong Lee
Cancer Communications (2021) Vol. 41, Iss. 10, pp. 937-967
Open Access | Times Cited: 34
Circulating Tumour DNA in Melanoma—Clinic Ready?
Ann Tivey, Fiona Britton, J S Scott, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 3, pp. 363-373
Open Access | Times Cited: 25
The future of targeted kinase inhibitors in melanoma
Signe Caksa, Usman Baqai, Andrew E. Aplin
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108200-108200
Open Access | Times Cited: 24
New prospectives on treatment opportunities in RASopathies
Bruce D. Gelb, Marielle E. Yohe, Cordula M. Wolf, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022) Vol. 190, Iss. 4, pp. 541-560
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top